Update: New Test Developed at Hadassah Predicts Presence of Harmful BRCA Mutation Which Can Trigger Breast Cancer
UPDATE: November 27, 2013
On November 27, The New York Times put the issue of breast cancer in Israel on their front page, highlighting the country's high rate of the cancer. National President Marcie Natan responded to the article mentioning Hadassah Medical Organization's groundbreaking work in discovering the mutation which triggers breast cancer and the development of the blood test which reveals its presence.
Israeli researchers, led by Dr. Asher Salmon, then Senior Oncologist at the Hadassah Medical Center, developed a blood test that reveals it is possible to predict the presence of harmful BRCA1 and BRCA2 mutations in otherwise healthy women using a novel technology called gene expression profiling. Women with a mutation in their BRCA1 or BRCA2 gene have a significantly increased risk for developing breast or ovarian cancer. For many of those at risk, the disease may develop at an early age.
"This novel technology aims to provide a layer of information regarding the cell functionality aspect of BRCA mutations that could greatly enhance the doctor's ability to identify high-risk carriers," explains Dr. Salmon. With gene expression profiling, researchers can search for genes that have the potential to distinguish healthy BRCA1 and BRCA2 mutation carriers from noncarriers.
The only other test available to detect these mutations is full gene sequencing; however, as Dr. Salmon points out, it is "expensive, time consuming and, in many cases, lacks clear and decisive information for making a clinical decision." Many times, it cannot be determined if the mutation is neutral or harmful.
New evidence has revealed that cells with a mutation in one of the two copies of the BRCA1 or BRCA2 genes display a distinct gene expression profile when they are exposed to elements that cause DNA damage, such as radiation. Knowing this, Dr. Salmon and his team collected white blood cells from the blood samples donated by 17 healthy women who had a mutated BRCA gene. They cultured the cells and then exposed them to radiation. Next, they extracted the RNA from these cells and compared it to the RNA from identically treated white blood cells from 10 healthy women who did not carry the BRCA gene. The researchers found that approximately 1500 genes were differentially expressed between carriers and noncarriers. They then narrowed this list to 18 genes that were the most significantly differentiated between the two groups of women.
The Sharett Institute of Oncology is a world leader in cancer research. Its staff is at the cutting edge of treatment of breast and ovarian cancer, melanoma, lung and pancreatic cancer and leukemia.
They validated their results with another two groups of women--40 carriers of the BRCA mutation and 17 noncarriers. Their validation model showed a sensitivity of 95 percent.
According to Dr. Salmon, the test can reveal whether a patient carries a harmful mutation regardless of the specificity of the mutation. "In societies where gene sequencing is not feasible, this test can substitute for it with a very high accuracy rate," Dr. Salmon relates.
Hadasit, Hadassah's technology transfer arm, identified the economic and scientific potential of this new development, protected it with a patent, and commercialized it to Biogene, a daughter company of Micromedic, which is working on developing a diagnostic kit based on the research.
The Israeli research team--which included Prof. Tamar Peretz, Director of Hadassah's Sharrett Institute of Oncology, and physicians from Tel Hashomer Hospital, Bar Ilan University, Barzilai Medical Center, and Ariel University Center--reported their findings in Cancer Prevention Research, a journal of the American Association for Cancer Research. "In summary," the researchers write, "our study provides insight into the biologic effect of heterozygous mutations in BRCA1 and BRCA2 genes in response to ionizing irradiation-induced DNA damage. We also suggest a set of 18 genes that can serve as a prediction and screening tool for BRCA1 or BRCA2 mutational carriers by using easily obtained lymphocytes."
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>